104 related articles for article (PubMed ID: 29061799)
1. Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to Chemotherapeutic Agents.
Sanomachi T; Suzuki S; Kuramoto K; Takeda H; Sakaki H; Togashi K; Seino S; Yoshioka T; Okada M; Kitanaka C
Anticancer Res; 2017 Nov; 37(11):6177-6188. PubMed ID: 29061799
[TBL] [Abstract][Full Text] [Related]
2. Aripiprazole, an Antipsychotic and Partial Dopamine Agonist, Inhibits Cancer Stem Cells and Reverses Chemoresistance.
Suzuki S; Okada M; Kuramoto K; Takeda H; Sakaki H; Watarai H; Sanomachi T; Seino S; Yoshioka T; Kitanaka C
Anticancer Res; 2016 Oct; 36(10):5153-5161. PubMed ID: 27798875
[TBL] [Abstract][Full Text] [Related]
3. A Small-molecule Kinase Inhibitor, CEP-1347, Inhibits Survivin Expression and Sensitizes Ovarian Cancer Stem Cells to Paclitaxel.
Togashi K; Okada M; Yamamoto M; Suzuki S; Sanomachi T; Seino S; Yamashita H; Kitanaka C
Anticancer Res; 2018 Aug; 38(8):4535-4542. PubMed ID: 30061219
[TBL] [Abstract][Full Text] [Related]
4. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer.
Yeh CT; Wu AT; Chang PM; Chen KY; Yang CN; Yang SC; Ho CC; Chen CC; Kuo YL; Lee PY; Liu YW; Yen CC; Hsiao M; Lu PJ; Lai JM; Wang LS; Wu CH; Chiou JF; Yang PC; Huang CY
Am J Respir Crit Care Med; 2012 Dec; 186(11):1180-8. PubMed ID: 23024022
[TBL] [Abstract][Full Text] [Related]
5. Rho-Associated Protein Kinase (ROCK) Inhibitors Inhibit Survivin Expression and Sensitize Pancreatic Cancer Stem Cells to Gemcitabine.
Takeda H; Okada M; Suzuki S; Kuramoto K; Sakaki H; Watarai H; Sanomachi T; Seino S; Yoshioka T; Kitanaka C
Anticancer Res; 2016 Dec; 36(12):6311-6318. PubMed ID: 27919951
[TBL] [Abstract][Full Text] [Related]
6. AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel.
Yamamoto M; Suzuki S; Togashi K; Sanomachi T; Seino S; Kitanaka C; Okada M
Anticancer Res; 2018 Dec; 38(12):6699-6706. PubMed ID: 30504379
[TBL] [Abstract][Full Text] [Related]
7. AS602801 Sensitizes Ovarian Cancer Stem Cells to Paclitaxel by Down-regulating MDR1.
Yamamoto M; Suzuki S; Togashi K; Sanomachi T; Seino S; Kitanaka C; Okada M
Anticancer Res; 2019 Feb; 39(2):609-617. PubMed ID: 30711936
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.
Karpel-Massler G; Kast RE; Westhoff MA; Dwucet A; Welscher N; Nonnenmacher L; Hlavac M; Siegelin MD; Wirtz CR; Debatin KM; Halatsch ME
J Neurooncol; 2015 Mar; 122(1):21-33. PubMed ID: 25524815
[TBL] [Abstract][Full Text] [Related]
9. KLF5 strengthens drug resistance of ovarian cancer stem-like cells by regulating survivin expression.
Dong Z; Yang L; Lai D
Cell Prolif; 2013 Aug; 46(4):425-35. PubMed ID: 23869764
[TBL] [Abstract][Full Text] [Related]
10. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
Wong JC; Bathina M; Fiscus RR
J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
[TBL] [Abstract][Full Text] [Related]
11. Arctigenin enhances chemosensitivity to cisplatin in human nonsmall lung cancer H460 cells through downregulation of survivin expression.
Wang HQ; Jin JJ; Wang J
J Biochem Mol Toxicol; 2014 Jan; 28(1):39-45. PubMed ID: 24395429
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X
FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223
[TBL] [Abstract][Full Text] [Related]
13. The combinatory effects of PPAR-γ agonist and survivin inhibition on the cancer stem-like phenotype and cell proliferation in bladder cancer cells.
Wang Y; Tan H; Xu D; Ma A; Zhang L; Sun J; Yang Z; Liu Y; Shi G
Int J Mol Med; 2014 Jul; 34(1):262-8. PubMed ID: 24820432
[TBL] [Abstract][Full Text] [Related]
14. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents.
Chen G; Xu S; Renko K; Derwahl M
J Clin Endocrinol Metab; 2012 Apr; 97(4):E510-20. PubMed ID: 22278418
[TBL] [Abstract][Full Text] [Related]
15. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of survivin contributes to antitumor activity in cisplatin-resistant ovarian cancer cells.
Jiang L; Luo RY; Yang J; Cheng YX
Mol Med Rep; 2013 Feb; 7(2):425-30. PubMed ID: 23229441
[TBL] [Abstract][Full Text] [Related]
17. Survivin knockdown enhances gastric cancer cell sensitivity to radiation and chemotherapy in vitro and in nude mice.
Shen X; Zheng JY; Shi H; Zhang Z; Wang WZ
Am J Med Sci; 2012 Jul; 344(1):52-8. PubMed ID: 22261621
[TBL] [Abstract][Full Text] [Related]
18. Influence of SiRNA targeting survivin on chemosensitivity of H460/cDDP lung cancer cells.
Yang H; Fu JH; Hu Y; Huang WZ; Zheng B; Wang G; Zhang X; Wen J
J Int Med Res; 2008; 36(4):734-47. PubMed ID: 18652770
[TBL] [Abstract][Full Text] [Related]
19. Reversal of cisplatin resistance in non-small cell lung cancer stem cells by Taxus chinensis var.
Jiang YQ; Xu XP; Guo QM; Xu XC; Liu QY; An SH; Xu JL; Su F; Tai JB
Genet Mol Res; 2016 Sep; 15(3):. PubMed ID: 27706681
[TBL] [Abstract][Full Text] [Related]
20. Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer.
Salzano G; Riehle R; Navarro G; Perche F; De Rosa G; Torchilin VP
Cancer Lett; 2014 Feb; 343(2):224-31. PubMed ID: 24099916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
